Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | ZDHHC9 | Q9Y397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28475644 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TDP1L3MBTL1 | |
| SCHEMBL10413244 | 0.84 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3MITFCA1 | |
| SCHEMBL22285003 | 0.84 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3MITFCA1 | |
| SCHEMBL6926417 | 0.84 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3MITFCA1 | |
| SCHEMBL4149173 | 0.82 | CA1 (0.47) | SLC6A2SLC6A4SLC6A3TDP1L3MBTL1 | |
| SCHEMBL12520753 | 0.82 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11734127 | 0.80 | SPHK1 (0.44) | SLC6A2SLC6A4SLC6A3TDP1L3MBTL1 | |
| SCHEMBL4933217 | 0.79 | MAPT (0.46) | CA1CA2CA4CA9 | |
| SCHEMBL13323425 | 0.77 | SLC6A4 (0.52) | SLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL12493858 | 0.75 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501828-B1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | disclosed |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-11-24 | — | — | US | disclosed |
| EP-1501828-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091249-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | PRDX5, PIR, GRIK5 | SLC6A2 385/4885SLC6A4 153/4885SLC6A3 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.